



Dynavax to Webcast Presentation at Friedman Billings Ramsey Conference

BERKELEY, Calif., May 23 /PRNewswire-FirstCall/ -- Dynavax Technologies (Nasdaq: DVAX) announced today that Dino Dina, M.D., President, CEO and Director, will present an overview of the company at the Friedman Billings Ramsey 9th Annual Growth Conference at the Millennium Broadway Hotel in New York City.

Dr. Dina's presentation will be webcast live at 3:20 p.m. EDT on Wednesday, June 1, 2005. The webcast presentation may be accessed by visiting <http://www.wsw.com/webcast/fbr10/dvax/>. The presentation can also be accessed by visiting the Dynavax website at <http://www.Dynavax.com> under the Investors section where it will also be archived for 30 days following the presentation.

About Dynavax

Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our clinical development programs are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. Dynavax's pipeline includes: a ragweed allergy immunotherapeutic, currently in a large-scale Phase 2/3 clinical trial, and in a supportive clinical trial in ragweed allergic children; a hepatitis B vaccine that is currently in a Phase 2/3 clinical trial; a cancer therapy currently in a Phase 2 clinical trial; and an asthma immunotherapeutic that has shown preliminary safety and pharmacology in a Phase 2a clinical trial.

SOURCE Dynavax Technologies Corporation
05/23/2005

CONTACT: Jane M. Green, Ph.D., Vice President, Corporate Communications of Dynavax Technologies Corporation, +1-510-665-4630, or jgreen@dvax.com/
Web site: <http://www.dynavax.com>
(DVAX)
05/23/2005 16:00 EDT <http://www.prnewswire.com>